Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone201-326-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$213.31 million
Profitability
Miscellaneous
Employees96
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions
What is Eagle Pharmaceuticals' stock symbol?
Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."
How will Eagle Pharmaceuticals' stock buyback program work?
Eagle Pharmaceuticals declared that its board has authorized a stock buyback plan on Thursday, August 10th 2017, which authorizes the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 13.3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board believes its shares are undervalued.
How were Eagle Pharmaceuticals' earnings last quarter?
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) released its earnings results on Thursday, February, 28th. The specialty pharmaceutical company reported $1.20 earnings per share for the quarter, topping analysts' consensus estimates of $1.16 by $0.04. The specialty pharmaceutical company had revenue of $56.05 million for the quarter, compared to the consensus estimate of $54.17 million. Eagle Pharmaceuticals had a net margin of 14.96% and a return on equity of 17.76%. The business's revenue was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.05 earnings per share. View Eagle Pharmaceuticals' Earnings History.
When is Eagle Pharmaceuticals' next earnings date?
What price target have analysts set for EGRX?
4 brokerages have issued 1 year price targets for Eagle Pharmaceuticals' stock. Their forecasts range from $41.00 to $66.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $54.75 in the next twelve months. This suggests a possible upside of 15.9% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals.
What is the consensus analysts' recommendation for Eagle Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.
What are Wall Street analysts saying about Eagle Pharmaceuticals stock?
Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "Eagle has carved out a leading position in the specialty pharma market via its 505(b) (2) strategy. We expect earnings revisions and pipeline readouts to drive EGRX stock going forward. We believe the risk-reward of such items are adequately reflected in the current stock price. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $58." (4/15/2019)
- 2. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (2/18/2019)
Has Eagle Pharmaceuticals been receiving favorable news coverage?
Media headlines about EGRX stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next few days.
Who are some of Eagle Pharmaceuticals' key competitors?
Some companies that are related to Eagle Pharmaceuticals include Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Insmed (INSM), Arena Pharmaceuticals (ARNA), Portola Pharmaceuticals (PTLA), PTC Therapeutics (PTCT), Uniqure (QURE), The Medicines (MDCO), Endocyte (ECYT), AnaptysBio (ANAB), Myokardia (MYOK), Nabriva Therapeutics (NBRV) and Supernus Pharmaceuticals (SUPN).
What other stocks do shareholders of Eagle Pharmaceuticals own?
Who are Eagle Pharmaceuticals' key executives?
Eagle Pharmaceuticals' management team includes the folowing people:
- Mr. Scott L. Tarriff, CEO & Director (Age 59)
- Mr. David M. Pernock, Pres & Chief Operating Officer (Age 66)
- Mr. Pete A. Meyers, Chief Financial Officer (Age 49)
- Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 58)
- Mr. Daniel O'Connor, Exec. VP of Biologics & Corp. Devel. (Age 39)
Who are Eagle Pharmaceuticals' major shareholders?
Eagle Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Chartwell Investment Partners LLC (1.49%), Scout Investments Inc. (0.39%), Campbell Newman Asset Management Inc. (0.07%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Sander A Flaum and Scott Tarriff. View Institutional Ownership Trends for Eagle Pharmaceuticals.
Which institutional investors are selling Eagle Pharmaceuticals stock?
Which institutional investors are buying Eagle Pharmaceuticals stock?
EGRX stock was acquired by a variety of institutional investors in the last quarter, including Campbell Newman Asset Management Inc.. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein and Pete A Meyers. View Insider Buying and Selling for Eagle Pharmaceuticals.
How do I buy shares of Eagle Pharmaceuticals?
Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eagle Pharmaceuticals' stock price today?
One share of EGRX stock can currently be purchased for approximately $47.23.
How big of a company is Eagle Pharmaceuticals?
Eagle Pharmaceuticals has a market capitalization of $657.63 million and generates $213.31 million in revenue each year. The specialty pharmaceutical company earns $31.90 million in net income (profit) each year or $2.09 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe.
What is Eagle Pharmaceuticals' official website?
How can I contact Eagle Pharmaceuticals?
Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]
MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
